JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $445

Benzinga Newsdesk www.benzinga.com Positive 84.7%

Neg 0% Neu 0% Pos 84.7%

JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $425 to $445.